Influence of Oxytocin on the Startle Reflex and on Its Modulation
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Oxytocin (OXT) is currently regarded as a crucial neuropeptide in the mediation of various human social behaviors, e.g. social affiliation, social recognition, and the modulation of anxiety, mood, and aggression. An impairment of social behavior, emotional regulation as well as increased stress reactions are characteristic of several psychiatric conditions, including schizophrenia, social anxiety and PTSD, in which there is also some evidence for OXT dysfunction. The startle reflex is a basic defensive reaction that can be modulated by emotional stimuli. The investigation of the startle reflex and of its modulation is a well-validated method to test stress reactions and emotional regulation. These processes are impaired in the same psychiatric diseases, in which OXT dysfunction was evidenced. Although previous animal studies showed that the dysfunction of brain OXT systems might be implicated in startle reflex and in its modulation, no study has been performed yet in human that investigated the influence of OXT administration on the startle response and on its affective modulation. A first aim of this study is to investigate the influence of OXT on stress reactivity and emotional modulation in healthy humans. A second aim is to develop a method for the investigation of anxiety disorders. Fifty male healthy participants will be tested using a randomized double-blind placebo-controlled cross-over design in two occasions; once with administration of 24 IU OXT, and once with placebo using nasal sprays while performing a computer-based experiment, in which emotional pictures and auditory startle probes are presented. We will measure the subject's subjective ratings of the pictures as well as the facial EMG activation, heart rate and electrodermal activation throughout the study. This project offers a unique opportunity to study the relationship between the OXT system and basic motivational and emotional behaviors. The investigation of these mechanisms is in turn greatly worthwhile, not only for understanding of the neurochemical and physiological processes involved in emotional regulation, but also for the comprehension of the neuroendocrine and neurophysiological mechanismsunderlying anxiety disorders. In the long term, it could open the possibilities of OXT as a psychobiological therapeutics of psychiatric disorders.
| Condition | Intervention |
|---|---|
|
Psychiatric Disorders |
Drug: Syntocinon® Drug: inactive nasal spray |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Basic Science |
| Official Title: | A Randomized, Double-blind, Placebo-controlled Single-center Study on the Influence of Oxytocin on the Startle Reflex and on Its Modulation in Healthy Male Subjects |
- Eye blink response to the tones measured as the peak activity of the left musculus orbicularis oculi that will be compared between the active drug and the placebo conditions. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- Anxiety ratings assessed with the State-Trait-Inventory that will used as a covariate in the ANOVAs. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 50 |
| Study Start Date: | May 2010 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: oxitocin nasal spray
oxytocin nasal spray
|
Drug: Syntocinon®
single dose of OXT (24 IU)
Other Name: Syntocinon®
|
|
Placebo Comparator: placebo
inactive nasal spray
|
Drug: inactive nasal spray
single dose (24 IU)
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- gender: male
- age > 18 years
- good command of German
- non-smoker
Exclusion Criteria:
- impaired cognitive abilities
- past or current psychiatric or neurological disorder
- other relevant somatic disease (including liver, kidney or heart diseases - -- allergy to preserving agents (Paraben contained in nasal spray)
- other medication including hormonal and herbal medication
- participation in other clinical studies within one month
- impaired hearing
Contacts and Locations| Contact: Chantal Martin Soelch, PhD | +41 80)44 255 ext 5280 | chantal.martinsoelch@usz.ch |
| Switzerland | |
| University Hospital Zurich, Division of Psychiatry and Psychotherapy | Recruiting |
| Zurich, Switzerland, 8091 | |
| Contact: Chantal Martin Soelch, PhD +41 (0)44 255 ext 5280 chantal.martinsoelch@usz.ch | |
| Principal Investigator: | Chantal Martin Soelch, PhD | University Hospital Zurich, Division of Psychiatry and Psychotherapy |
More Information
No publications provided
| Responsible Party: | University of Zurich |
| ClinicalTrials.gov Identifier: | NCT01066299 History of Changes |
| Other Study ID Numbers: | OXT_PSY1 |
| Study First Received: | February 2, 2010 |
| Last Updated: | November 28, 2011 |
| Health Authority: | Switzerland: Swissmedic |
Keywords provided by University of Zurich:
|
oxytocin psychophysiology startle |
anxiety emotion physiology |
Additional relevant MeSH terms:
|
Mental Disorders Oxytocin Oxytocics Reproductive Control Agents |
Physiological Effects of Drugs Pharmacologic Actions Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013